Survival and Prognostic Determinants after IMRT and 3D Radiotherapy in Metachronus Bone – Only Spinal Metastasis of Breast Cancer: A Prospective Phase II Trial
1
Radiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University, Assuit, Egypt.
2
Lecture of Clinical Oncology, Assuit University, Assuit, Egypt.
Abstract
Objectives: Oligometastasis is a distinctive subset of osseous metastatic breast cancer, represented by single or few detectable metastatic osseous lesions. A more advanced radiotherapy approach can be considered in those bone-only diseases. We analysed different predictive factors affecting the 5-year survival after palliative radiotherapy in patients with bone-only metastatic breast cancer. Methods: This prospective multicentre phase II study included 60 breast cancer patients with metachronus osseous oligometastasis in the period from January 2019 to January 2024. Result: The mean age of our patients was 49.55±6.39 (40-67), and the median follow-up time was 45 months. The mean survival time from metastasis and radiotherapy was 41.11 (36.33-45.89), and 49.64 (44.11-55.16), respectively. The three-year bone survival rate was 81.7% and the five-year survival rate was 79%. In the univariate analysis, the significant prognostic factors that were associated with poor OS were: age more than 50 years old, multiple metastasis, higher level of LDH , anemic patients, triple negative disease, 3D planning and dose less than 3000/10GY. Multivariate analysis confirmed 2 independent prognostic factors for longer survival: triple-positive histology (p=0.0001), and intended radiation dose more than or equal 30 Gy (p=0.028). Conclusion: Prolonged radiotherapy fractionation schedules improve survival in triple positive bone-only metastatic breast cancer with controlled primary. Simple blood tests should not be routinely done in those patients.
Youssif, A. , Abdellah, A. , El-Morshidy, S. and Hasaballah, A. (2025). Survival and Prognostic Determinants after IMRT and 3D Radiotherapy in Metachronus Bone – Only Spinal Metastasis of Breast Cancer: A Prospective Phase II Trial. Asian Pacific Journal of Cancer Prevention, (), -.
MLA
Youssif, A. , , Abdellah, A. , , El-Morshidy, S. , and Hasaballah, A. . "Survival and Prognostic Determinants after IMRT and 3D Radiotherapy in Metachronus Bone – Only Spinal Metastasis of Breast Cancer: A Prospective Phase II Trial", Asian Pacific Journal of Cancer Prevention, , , 2025, -.
HARVARD
Youssif, A., Abdellah, A., El-Morshidy, S., Hasaballah, A. (2025). 'Survival and Prognostic Determinants after IMRT and 3D Radiotherapy in Metachronus Bone – Only Spinal Metastasis of Breast Cancer: A Prospective Phase II Trial', Asian Pacific Journal of Cancer Prevention, (), pp. -.
CHICAGO
A. Youssif , A. Abdellah , S. El-Morshidy and A. Hasaballah, "Survival and Prognostic Determinants after IMRT and 3D Radiotherapy in Metachronus Bone – Only Spinal Metastasis of Breast Cancer: A Prospective Phase II Trial," Asian Pacific Journal of Cancer Prevention, (2025): -,
VANCOUVER
Youssif, A., Abdellah, A., El-Morshidy, S., Hasaballah, A. Survival and Prognostic Determinants after IMRT and 3D Radiotherapy in Metachronus Bone – Only Spinal Metastasis of Breast Cancer: A Prospective Phase II Trial. Asian Pacific Journal of Cancer Prevention, 2025; (): -.
)